1974•Drug and Therapeutics BulletinRequires access

Lincomycin, clindamycin and pseudomembranous colitis

Author information unavailable

Open publisher page 0 citations

Abstract

Lincomycin (Lincocin - Upjohn; Mycivin - Boots) and clindamycin (Dalacin C - Upjohn) are widely used for the treatment of a variety of infections.1 2 Until now they have been considered to have virtually no serious unwanted effects.3 The most common unwanted effect has been diarrhoea, which occurs in 10% or more of patients treated with lincomycin; this has only occasionally been severe enough to lead to the discontinuation of the drug. Recent reports, however, show that both lincomycin4 and clindamycin5 6 can cause a colitis which on gross and microscopic examination resembles pseudomembranous colitis, and which in some cases has been fatal. The condition has apparently occurred after both oral and parenteral administration of clindamycin.6

About this research paper

What this paper is about

Lincomycin (Lincocin - Upjohn; Mycivin - Boots) and clindamycin (Dalacin C - Upjohn) are widely used for the treatment of a variety of infections.1 2 Until now they have been considered to have virtually no serious unwanted effects.3 The most common unwanted effect has been diarrhoea, which occurs in 10% or more of patients treated with lincomycin; this has only occasionally been severe enough to lead to the discontinuation of the drug. Recent reports, however, show that both lincomycin4 and clindamycin5 6 can cause a colitis which on gross and microscopic examination resembles pseudomembranous colitis, and which in some cases has been fatal. The condition has apparently occurred after both oral and parenteral administration of clindamycin.6

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Lincomycin (Lincocin - Upjohn; Mycivin - Boots) and clindamycin (Dalacin C - Upjohn) are widely used for the treatment of a variety of infections.1 2 Until now they have been considered to have virtually no serious unwanted effects.3 The most common unwanted effect has been diarrhoea, which occurs in 10% or more of patients treated with lincomycin; this has only occasionally been severe enough to lead to the discontinuation of the drug. Recent reports, however, show that both lincomycin4 and clindamycin5 6 can cause a colitis which on gross and microscopic examination resembles pseudomembranous colitis, and which in some cases has been fatal. The condition has apparently occurred after both oral and parenteral administration of clindamycin.6

Key concepts: Lincomycin, Clindamycin, Pseudomembranous colitis, Medicine, Discontinuation, Colitis, Antibiotics, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Lincomycin, clindamycin and pseudomembranous colitis — Research Paper | ScholarLens